NanoXplore Announces Results of Annual Meeting of Shareholders

NanoXplore Inc. ("NanoXplore" or the "Company") ( TSX: GRA and OTCQX: NNXPF ), a world-leading graphene company, held its Annual Meeting of Shareholders (the "Meeting") virtually on December 22, 2021. Altogether, 85,364,604 shares (53.99% of outstanding common shares) were accounted for at the Meeting. As part of the formal proceedings, the Company's shareholders elected the Board of Directors and approved the appointment of PricewaterhouseCoopers LLP as independent auditor of the Company. The complete voting results from the Meeting are presented below.

Election of Directors

The Board of Directors fixed at eight the number of directors of the Company to be elected at the Meeting. Each of the eight nominees listed in the Management Information Circular was elected as a director of NanoXplore.   All of the nominee directors were already members of the Board of Directors of the Company.

Nominee Votes For % For Votes Withheld % Withheld
Rob Wildeboer 82,313,650 99.99% 9,200 0.01%
Benoît Gascon 81,089,450 98.50% 1,233,400 1.50%
Soroush Nazarpour 82,318,900 99.99% 3,950 0.01%
Cameron Harris 82,317,650 99.99% 5,200 0.01%
Denis Labrecque 80,999,157 98.39% 1,323,693 1.61%
Arinder S. Mahal 82,188,217 99.84% 134,633 0.16%
Jodie Morgan 82,197,767 99.85% 125,083 0.15%
Nathalie Pilon 82,312,100 99.99% 10,750 0.01%

Appointment of Independent Auditor

PricewaterhouseCoopers LLP, Chartered Professional Accountants, was reappointed as independent auditor of NanoXplore until the close of the next Annual mMeeting of Shareholders, and the directors were authorized to fix the remuneration of the auditor.

Votes For % For Votes Withheld % Withheld
84,344,155 99.98% 18,539 0.02%

About NanoXplore

NanoXplore is a graphene company, a manufacturer and supplier of high-volume graphene powder for use in industrial markets. The Company provides standard and custom graphene-enhanced plastic and composite products to various customers in transportation, packaging, electronics, and other industrial sectors. NanoXplore is headquartered in Montreal, Quebec with manufacturing facilities in Canada, the United States and Europe.

For more information, please contact:

Soroush Nazarpour
President & CEO
NanoXplore Inc.
info@NanoXplore.ca
(514) 935-1377


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

GRA:CA,NNXPF
The Conversation (0)
Sona Nanotech

Sona Nanotech Grants Options

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that it has granted 25,000 incentive stock options under the Company's Stock Option Plan ("Option Plan") to a consultant. Each option is exercisable into one common share at a price of $0.30 per share and will vest at the rate of 25% every six months. The options will expire five years from the date of grant. All other terms and conditions of the options are in accordance with the terms of the Company's Option Plan.

Contact:
David Regan, CEO
+1-902-536-1932
david@sonanano.com

Keep reading...Show less
Sona Nanotech

Sona Nanotech


Keep reading...Show less
Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024

Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024

Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will participate in the Emerging Growth Virtual Conference taking place June 12-13, 2024.

Details for the Company's presentation:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Veru to Present at the American Diabetes Association's 84th Scientific Sessions

Veru to Present at the American Diabetes Association's 84th Scientific Sessions

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present two presentations at the American Diabetes Association's 84 th Scientific Sessions, taking place June 21-24, 2024, in Orlando, Florida.

The presentations are:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

  • Dr. Selvaggi was instrumental in the development and approval of lung cancer drugs Zykadia for Novartis and Opdivo for Bristol Myers Squibb
  • CEL-SCI's Multikine immunotherapy improves the 5-year survival of head and neck cancer patients to 73% compared to 45% in controls and cuts the 5-year risk of death by 50%
  • FDA has given CEL-SCI the go-ahead to commence a confirmatory Registration Study for Multikine for the target population in head and neck cancer
  • Dr. Selvaggi will be supporting CEL-SCI to bring Multikine to patients through a confirmatory registrational path that has been agreed with regulatory authorities and that has a potential for cure

CEL-SCI Corporation (NYSE American: CVM) today announced Dr. Giovanni Selvaggi, an oncology key opinion leader instrumental in successfully bringing several drugs to market has joined CEL-SCI as a Clinical Advisor. Dr. Selvaggi joins CEL-SCI as the Company recently received its go-ahead from the U.S. Food and Drug Administration (FDA) for its confirmatory Registration Study of Multikine* in the treatment of head and neck cancer.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240606671425/en/

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers

VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice

Additive effects were observed for VTX3232 in combination with the GLP-1 receptor agonist semaglutide across key endpoints compared to semaglutide or VTX3232 alone

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×